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Abstract
Introduction Creatine supplementation has
consistently been demonstrated to augment adaptations
in body composition, muscle strength and physical
function in a variety of apparently healthy older
adults and clinical populations. The effects of creatine
supplementation and resistance training in individuals
with cancer have yet to be investigated. This study aims
to examine the effects of creatine supplementation
in conjunction with resistance training on body
composition, muscle strength and physical function
in prostate cancer patients undergoing androgen
deprivation therapy.
Methods and analysis This is a randomised, doubleblind, placebo-controlled trial designed to examine
the effects of creatine supplementation in addition
to resistance training in patients with prostate
cancer receiving androgen deprivation therapy. Both
supplement and placebo groups will receive a 12-week
supervised exercise programme comprising resistance
training undertaken three times per week. The primary
endpoint (fat-free mass) and secondary endpoints (fat
mass, per cent body fat, physical fitness, quality of life
and blood biomarkers) will be assessed at baseline and
immediately following the intervention.
Ethics and dissemination The Human Research Ethics
Committee of Edith Cowan University approved this
study (ID: 22243 FAIRMAN). If the results of this trial
demonstrate that creatine supplementation can augment
beneficial adaptations of body composition, physical
function and/or psychosocial outcomes to resistance
training, this study will provide effect sizes that will
inform the design of subsequent definitive randomised
controlled trials. The results of this study will be
published in peer-reviewed journals and presented at
various national and international conferences.
Trial registration number ACTRN12619000099123

 1,2,4

Strengths and limitations of this study
►► This is the first trial designed to examine the effects

of creatine supplementation and resistance training on body composition in patients with prostate
cancer, addressing a critical area of concern in this
population.
►► Both groups receive an exercise intervention which
may enhance recruitment affording all patients the
benefits of exercise and negates questions surrounding attention control.
►► The study is limited to men with prostate cancer on
androgen deprivation therapy and results may not
be generalised to other populations.
►► The inclusion of dietary analysis at baseline, 6-week
midpoint and 12-week follow-up will offer additional
insight into dietary habits of participants that may
influence muscle hypertrophy (ie, protein intake).
►► The lack of follow-up assessments limits information on the sustainability of benefit.

Introduction
Androgen deprivation therapy (ADT) is
frequently incorporated into the management of men with localised and advanced
prostate cancer (PCa).1 Unfortunately, the
catabolic effects of ADT result in loss of fat-free
mass (FFM), increased fat mass, reduced
muscle strength and lower bone mineral
density (BMD).2–5 In turn, these adverse
effects of ADT are linked with functional
decline (ie, reduced walking speed, ability to
rise from a chair or climb stairs, etc), frailty,
and increased risk for cardiovascular disease,
metabolic syndrome and osteoporosis.6 Thus,
patients with PCa endure long and lingering
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impacts on physical function, health status and quality of
life (QOL) that accompany ADT as a ‘trade-off’ for more
effective cancer control and extended longevity.
Resistance training has gained increasing attention in
the recent years, with the results from numerous studies
supporting resistance training as a promising strategy to
counteract declining body composition, BMD and physical function mediated by ADT.7–11 Nevertheless, there
remains a pronounced exacerbation of normal ageing
(decline in lean body mass, muscular strength and endurance) as a result of ADT, resulting in an accelerated trajectory towards a ‘disability’ condition (ie, the difficulty or
reduced ability to perform activities essential to independent living).12 Consequently, there is an urgent need for
strategies to augment resistance training adaptations and
further target the worsening of body composition, muscle
strength and physical function in this population.6 13–15
More recently, there has been greater emphasis on the
need for multimodal strategies combining exercise and
dietary/supplementation interventions to more aggressively target.
FFM in patients with cancer.16 Creatine (Cr) is one of the
most widely studied supplements (SUPPs), with research
consistently demonstrating greater improvements in
FFM, strength and physical function when combined with
resistance training, compared with that achieved with
resistance training alone.17–22 Further, emerging research
has demonstrated the efficacy of Cr supplementation for
improving FFM, BMD, muscle strength and physical function in older adults or clinical populations with similar
muscle wasting characteristics to cancer, such as muscular
dystrophy and HIV.23–30
Cr supplementation increases intramuscular stores of
phosphocreatine (PCr), a high-energy phosphate that
plays a critical role in energy provision during exercise.31
It is hypothesised that Cr uptake by skeletal muscle is
modulated by muscle activity.32 Importantly, the ability to
sustain exercise effort is dependent on PCr availability,
which diminishes with intense exercise. Increases in
PCr stores may contribute to an accelerated resynthesis
of adenosine triphosphate (ATP) during exercise.19 20
Consequently, the ergogenic effects of Cr supplementation are likely a result from an increase in overall training
volume and/or quality,19 20 due to increases in intramuscular PCr stores32 33 enhancing exercise capacity. Taken
collectively, there is the potential that Cr supplementation may enhance the quality and/or quantity of resistance training in patients with PCa, leading to augmented
adaptations in FFM, muscle strength and/or function.16
Given the overwhelming evidence of Cr supplementation
in other populations, there is large therapeutic potential
for its use in patients with PCa.16
The primary aim of this study is to examine the effects
of Cr supplementation in conjunction with resistance
training on body composition, muscle strength and physical function in patients with PCa undergoing ADT. It is
hypothesised that resistance training plus Cr will lead to
greater improvements in FFM, muscle strength, QOL and
2

physical function than that of resistance training alone.
The results of this study will provide insights into the
effects of Cr supplementation as a potential low-cost therapeutic agent to target FFM in men with PCa receiving
ADT.

Methods
Study design
This is a randomised, double-blind, placebo (PLA)-controlled trial designed to examine the effects of Cr
supplementation in addition to resistance training
in patients with PCa receiving ADT. Both SUPP and
PLA groups will receive a 12-week supervised exercise
programme comprising of resistance training undertaken three times per week. In addition, participants in
the SUPP group will receive a daily dose of Cr: 20 g/
day during a loading phase of 5 days (the last 5 days of
the familiarisation period, described in detail later) and
then 5 g/day thereafter for the duration of the 12-week
exercise intervention. Participants in the PLA group
will follow the same dosing protocol with dextrose.
There will be a 2-week testing/familiarisation period
(detailed further in this manuscript) prior to the beginning of the intervention, with post-testing occurring in
the 2 weeks following the intervention. Consequently,
the total length of the study is approximately 16 weeks.
An overview of the study design and participant flow is
depicted in figure 1.
Participants
Fifty-six men (n=56) with localised or locally advanced
PCa, who are currently on ADT (and expected to
remain on ADT for at least 4 months postrecruitment),
will be eligible to enrol in this study. Participants will
be excluded if they have any visceral or bone metastases (ie, advanced or castrate-resistant PCa); are being
treated for any secondary or other cancers or are
currently participating in regular structured resistance
training (>2 days/week for 6 months) or are receiving
medications known to alter body composition (ie, corticosteroids, metformin, etc). Individuals who are participating in regular structured aerobic training (>2 days
a week) will not be excluded. Baseline activity will be
recorded and participants enrolled in the study will
be asked not to modify outside activity. Additionally,
participants will be excluded if they have taken Cr in
the previous 6 months.
Recruitment
Participants will be recruited through a variety of avenues
in Perth, Western Australia. Primarily, participants will
be approached by their attending specialist, who will
discuss details of the trial and provide individuals with a
study information sheet and referral to the study coordinator, who will verify eligibility by a telephone conversation. Additionally, flyers will be posted throughout local
medical clinics in the Perth area. All participants must
Fairman CM, et al. BMJ Open 2019;9:e030080. doi:10.1136/bmjopen-2019-030080
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Figure 1

Overview of study design.

receive physician clearance and provide informed consent
prior to participation in the trial. Proposed participant
flow throughout the study is presented in figure 2.
Measurements
Baseline and follow-up assessments will be undertaken
within 2 weeks of the participant beginning or completing
the intervention, respectively. An overview of assessments
and timeline of study activities is outlined in table 1.
Randomisation
Following baseline assessments (ie, on day 4 of familiarisation phase, following completion of strength and
physical function testing), consenting participants will
be randomised in a ratio of 1:1 to either SUPP or PLA
using computer-generated random assignment by a
member of the study team with no contact with participants. Participants will be stratified according to time on
ADT (≤6 and >6 months), age (≤65 and >65 years) and
randomly assigned to one of the two groups. All participants and members of the study team will be blinded to
group allocation.
Primary endpoint
Fat free mass
Whole body FFM and appendicular (lower and upper
limb) skeletal muscle mass will be assessed using dual-energy X-ray absorptiometry (Horizon A, Hologic, Massachusetts, USA) in accordance with Hart et al.34 Participants
will be asked to avoid strenuous exercise for 24 hours
prior to testing. Further, they will be instructed to avoid
the consumption of food and water 4 hours and 1 hour
prior to testing, respectively.

Participants will be asked to perform a general warmup, followed by two exercise-specific warm-up sets (4–6
repetitions), separated by 90–180 s. Participants will then
be asked to complete a maximal attempt (the maximal
amount of weight an individual can lift with proper technique through a full range of motion). Several maximal
lifts will be attempted (separated by 3–5 min) until the
participant reaches a weight that cannot be lifted using
proper technique. Efforts will be made to ensure a 1RM is
reached in as few attempts as possible.
QOL and fatigue
Health-related QOL for general health, pain, vitality,
social functioning, emotional role and mental health will
be assessed using the Medical Outcomes Short Form 36
V.2.35 Cancer-specific QOL indices will be measured using
the European Organisation for Research and Treatment
of Cancer (EORTC) Quality of Life Questionnaire-C30
and EORTC PR-25,36 37 assessing physical, emotional,
cognitive and sexual functioning, along with PCa-specific
symptoms. Cancer-related fatigue will be assessed using
the Functional Assessment of Chronic Illness Therapy-Fatigue questionnaire.38

Secondary endpoints
Muscle strength
Dynamic muscle strength will be assessed using one-repetition maximum (1RM) tests for chest press, seated row
and leg press exercises.7 15 1RM tests are the standard
by which muscular strength is evaluated and have been
used in prior investigations in individuals with cancer.7 15

Physical fitness
A battery of standard tests will be used to assess physical function, including the 400 m walk test; the timed
up-and-go test, and repeated chair rise test to assess physical function.7 15 The 400 m walk test will be completed in a
corridor/hallway with two cones spaced 20 m apart. Individuals will be asked to walk around the cones as quickly as
possible, completing a total of 10 laps, with the total time
to completion recorded. The timed up-and-go test will be
completed with a chair and a cone placed 3 m away. Individuals will be instructed to begin the test seated in the
chair, then instructed to get up, walk around the cone
and sit back down, with the total time for 1 lap recorded.
For the timed-up-and-go test and repeated chair rise, the
chair will be placed against a wall to ensure the safety of
participants. The repeated chair rise will be completed
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Figure 2

CONSORT diagram. CONSORT, Consolidated Standards of Reporting Trials.

by having the patient sit in a chair, and asked to rise to a
full standing position, sit back down and repeat five times
as quickly as possible, with the total time recorded as the
performance measure.

diseases, etc) will be obtained via questionnaires prior to
baseline testing, and will be actively monitored through
out the trial to capture any changes.

Other measures
Medical history
Information pertaining to cancer-specific (treatment
history, time on treatment, stage of cancer and time since
diagnosis, etc) and general medical history (comorbidities, lifestyle, concomitant medications and other chronic

Diet recall
Additionally, participants will be asked to complete a
3-day food record of the days preceding baseline testing.
They will be asked to replicate this diet for post-testing.
Further, a 3-day diet recall will be completed at midpoint
to gain further information about dietary changes that
may occur throughout the study.

4
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Table 1 Overview of testing and timeline of study activities
Time point

Week 1

Week 2

Week 15

Informed consent
Medical history and demographics

x
x

3-day food recall

x

x

Body composition (DXA)

x

x

Week 16

1RM, (leg press, chest press, seated row)

 

x

x

Physical function (400 m walk; timed up-and-go test; repeated
chair rise)

 

x

x

Quality of life (SF-36, EORTC-QLQ-C30; EORTC-PR25; FACIT-F)

x

Gastrointestinal questionnaire
Blood draw

x
x

x
x

x
x

DXA, dual-energy X-ray absorptiometry; EORTC-PR25, European Organisation for Research and Treatment of Cancer Prostate Cancer
Module; EORTC-QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; FACIT-F, Functional
Assessment of Chronic Illness Therapy-Fatigue; 1RM, one repetition maximum; SF-36, Short Form 36.

Anthropometrics
Height will be recorded to the nearest 1 cm using a wallmounted stadiometer (Model 222, Seca, Hamburg, DE),
with body mass recorded to the nearest 0.1 kg using an
electronic scale (AE Adams CPW Plus-200, Adam Equipment, Connecticut, USA).
Adverse effects
In order to examine any potential side effects of supplementation in this population, fasted blood samples will
be collected and analysed commercially by an accredited
National Association of Testing Authorities laboratory
(Australian Clinical Labs, Perth, Australia) for creatinine
at baseline and follow-up. Additionally, participants will
be asked to complete questionnaires related to gastrointestinal distress (nausea, bloating and upset stomach, etc)
and muscle cramping.19 Accredited exercise physiologists
(AEPs, Exercise and Sport Science Australia) will supervise the exercise sessions, ensuring correct technique and
appropriate progression, minimising the risk of adverse
events. Consequently, a data monitoring and safety
committee has not been appointed. However, participants
will be consistently monitored for any adverse effects, and
other disease-related or exercise-related adverse events
using adverse event logs across each patient’s on-trial
period, throughout the testing and training sessions.
Adverse events will be documented in accordance with
Exercise Medicine Research Institute (EMRI) standards
and reported to the HREC. Additionally, the participant
will be referred to their general practitioner or specialist,
as appropriate for a medical assessment of any adverse
event. Participants are free to withdraw from the study at
any time.

technique. Specifically, participants will undergo baseline
body composition testing on day 1. Following 2 days of
learning correct exercise technique, they will perform
baseline strength and physical function testing (day 4).
They will also begin the 5-day loading protocol for supplementation (outlined below) on day 4 in an effort to
ensure intramuscular Cr stores are saturated prior to the
beginning of the exercise programme. Further details on
the familiarisation/testing phase are outlined in table 2.

Familiarisation and baseline testing
All participants enrolled in the study will undergo a 2-week
familiarisation/testing period, where they will complete
baseline testing, begin the supplementation protocol
and receive instruction on safe and appropriate exercise

Exercise programme
Participants assigned to each arm will attend a total of
36 supervised exercise sessions for 12 weeks (thrice
weekly, with a minimum 48 hours rest between sessions).
Currently, the EMRI has four exercise clinics across Perth.
Participants will be given the option to choose the clinic
that is closest/most convenient for them to complete their
training and all sessions will be supervised by an AEP. The
resistance training programme will comprise eight exercises targeting large muscle groups of the body (leg press,
deadlift, step up, chest press, push-ups, shoulder press,
lat pulldown and seated row). The initial loading will be
equivalent to ~65% 1RM (3 sets of 12 reps), progressing
towards ~80% 1RM (4 sets of 8 reps). Loading will be
progressed throughout the programme using the ‘2 for
2 rule’, whereby if a participant can complete two additional reps on the last set of an exercise for two consecutive sessions, the weight for an exercise (~5% to 10%
for upper body; ~10% to 15% for lower body) will be
increased. Concurrently, repetitions will gradually
decrease across the programme to match the increase in
weight. This type of resistance training protocol (ie, exercises that stimulate large muscle groups, multiple sets and
short rest) has been recommended to enhance the hypertrophic response to training.39 40 The programme will be
autoregulated where variations in participants’ fatigue,
recovery, energy and physical capacity will be used to
adjust each training session. This model of autoregulation
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Table 2 Familiarisation and testing phase
Week 1 familiarisation
Day 1
3-day food record
DXA
Questionnaires

Day 2
2 sets x 8 reps (12RM)

Day 3
2 sets x 10 reps (12RM)

Day 5
2 sets X 10 reps

Day 6
2 sets X 12 reps

Week 2 familiarisation and test
Day 4
1RM
Chest press, seated row, leg press
Physical function
400 m walk, TUG, repeated chair rise
Start loading protocol (4×5 g SUPP or PLA)

DXA, dual-energy X-ray absorptiometry; PLA, placebo; reps, repetitions; 1RM, one repetition maximum; SUPP, supplement; TUG, timed up
and go.

has been previously proposed and currently being used in
other exercise oncology trials. Moreover, any deviations
to the protocol will be recorded in detail and reported in
the final manuscript. Specific details of the programme
are outlined in table 3.
Adherence
Adherence to the resistance training protocol will be
reported as a function of how much of the programme
was actually completed versus what was initially
Table 3 Outline of the 12-week exercise programme
characteristics
Weeks

Sets

Reps

Rest (seconds)

1–4

3

12

60

5–8

3

10

60

9–10

3

8

60

10–12

4

8

60

 

Day 1

Day 2

Day 3

Exercise
order

1.Deadlift

1.Push ups*

1.Deadlift

2.Leg press

2.Lat pulldown 2.Leg press

3.Push ups*

3.Chest press

3.Push ups*

4.Seated row

4.Seated row

4.Seated row

5.Step up

5.Shoulder
press

5.Step up

6.Chest press

6.Deadlift

6.Chest press

7.Pulldown

7.Step up

7.Pulldown

8.Shoulder
press

8.Leg press

8.Shoulder
press

*Push-ups will be performed on a Smith machine, where
the initial height of the bar will be adjusted to a point where
individuals can perform 12 repetitions. The exercise will
be progressed by lowering the bar (15 cm intervals) when
participants can successfully complete all repetitions. When
participants can complete all repetitions on the floor with good
technique, they will be progressed to a free weight bench press
movement.

6

planned. Specifically, volume load (sets x reps x weight)
will be used to calculate planned training volume for
each session. The training volume that was actually
completed will be recorded. Any modifications to the
exercise programme will be made at the discretion of
the AEPs supervising the exercise programme. How
and why sessions were modified will be recorded and
reported in the final manuscript. The adherence to exercise will be reported as a ratio of completed to planned
cumulative exercise, expressed as a percentage, previously outlined by Nilsen et al.41 Additionally, reasons for
missing a session will also be reported, with rescheduling of sessions permitted.
SUPP and PLA protocol
Participants in the SUPP group will receive 20 g/day of
Cr monohydrate for 5 days, beginning on day 4 of the
familiarisation/testing phase (immediately after randomisation, approximately 7 days prior to first training
session), divided into four equal doses throughout the
day. Participants will then be given single daily doses of
5 g for the duration of the 12-week training programme.
This dosing protocol has been previously demonstrated
to be safe and efficacious in older adults.18 22 25 27 Consequently, the loading phase prior to the beginning of the
resistance training programme was included to ensure
intramuscular Cr stores were saturated prior to resistance
training to ‘maximise’ the likelihood of seeing an effect
of supplementation.20 Participants in the PLA group will
follow the same dosing protocol with dextrose. Dextrose
is inert in terms of training adaptations and has been
used as PLA in prior supplementation trials.18 42 Participants will be asked to dissolve the SUPPs in 200–300
mL of juice (orange or apple) to mask the solubility
of Cr and taste of dextrose. To increase compliance,
participants will be asked to return empty packets to the
research team once a week. SUPP packages will be coded
so that neither the investigators nor the participants will
be aware of contents.
Fairman CM, et al. BMJ Open 2019;9:e030080. doi:10.1136/bmjopen-2019-030080
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Statistical analysis
To achieve 80% power at an alpha level of p<0.05 (two
tailed), 25 participants per group would be required to
detect a mean difference in change between the two
groups for FFM of 1.4 kg at the end of the 12-week intervention, based on our previous work in men receiving
ADT11 and work by Brose et al18 investigating changes in
body composition and muscle strength with Cr supplementation and resistance training in older adults. To
account for an attrition rate of ~10% seen in prior trials,7 43
we aim to recruit 56 participants (SUPP n=28; PLA n=28).
Statistical analysis will be conducted using SPSS (V.25,
IBM). Normality of the distribution will be assessed using
the Kolmogorov-Smirnov test. Summary descriptive statistics will be used for participant characteristics. Baseline
characteristics will be assessed using independent t-tests
or the Mann-Whitney U test, as appropriate. Separate
group (Condition: SUPP, PL) x time (baseline, follow-up)
repeated-measures analyses of variance or analyses of
covariance, where appropriate, will be performed for
each endpoint. Any data not normally distributed will
be log transformed (ln) for analysis. For categorical variables, Pearson X2 test will be used. Per-protocol analysis
as well as an intention-to-treat approach with multiple
imputations will be used to examine the data. Data will be
deidentified and coded to classify which group the participant is in, without any ability to identify the individual.
Identifiable documents will be destroyed, with deidentified information kept in a password protected electronic
folder only accessible to the study team.

conferences. The results of the trial will also be presented
to all study participants (individually and collectively),
and the EMRI team will work with local community
members and support groups to develop materials for
plain language summaries and dissemination.

Ethics and dissemination
Any protocol amendments will be submitted to the
ethics committee for approval and these changes will
be reflected in the trial registration. If the results of this
trial demonstrate that Cr supplementation can augment
adaptations of body composition, physical function and/
or psychosocial outcomes to resistance training, this study
will provide effect sizes that will inform the design of subsequent definitive randomised controlled trials. The results
of this study will be published in peer-reviewed journals
and presented at various national and international

Discussion
Despite well-documented clinical benefits as a PCa treatment, ADT is consistently associated with profound
worsening of muscle mass, neuromuscular strength and
physical function in men with PCa.2–5It has been postulated that reductions in muscle strength and physical function contribute to the cascade of physiological decline in
men with PCa receiving ADT, ultimately resulting in a
disability condition.6 44 This contributes to a decline in
activities of daily living, social activities and QOL.6 44 As
a result, men with PCa are at a heightened risk of frailty,
falls and fractures, and early mortality.3 5 6 Further, the
decline in body composition is also associated with sarcopenic obesity, leading to increases in cardiometabolic risk
factors.45 46 Consequently, investigations into strategies
that may improve musculoskeletal health is of critical
importance in this population.
An ever-increasing body of literature supports the benefits of exercise, in particular resistance training, to counteract the loss of muscle mass and strength in men with
PCa receiving ADT.9 10 44 47 Recently, trials have emerged
examining the potential for nutritional supplementation to augment adaptations to resistance training in
men with PCa receiving ADT.48–50 Cr is one of the most
widely studied SUPPs, with increasing application across a
breadth of populations.17 51–58 Of particular relevance, Cr
supplementation has been consistently demonstrated to
enhance FFM in vulnerable populations that experience
similar issues with loss of muscle mass to PCa, such as HIV,
muscular dystrophy and older adults.23–30 Results from a
recent meta-analysis by Chilibeck et al59 demonstrate that
Cr supplementation, in addition to resistance training, can
result in ~1.4 kg greater increase in FFM compared with
resistance training alone in older adults. The authors also
reported that Cr supplementation, in addition to resistance training, resulted in a greater increase in upper and
lower body strength.59 Given the consistent reduction in
FFM, muscle strength and physical function in men with
PCa receiving ADT, particularly compared with apparently healthy controls, these results highlight the considerable therapeutic potential of Cr supplementation to
more effectively ameliorate treatment-related side effects
in this population. The safety of Cr is well established in a
variety of apparently healthy and clinical populations, yet
no research to date has investigated Cr supplementation
in individuals with cancer.16 Consequently, the inclusion
of questions on gastrointestinal distress and creatinine
as a marker of kidney function will provide invaluable
insight into the potential (or lack thereof) side effects of
Cr supplementation in this population.
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Patient and public involvement
EMRI regularly communicates with consumer representatives (individuals with cancer and their caregivers) with
an acute understanding of cancer treatment-related side
effects and the broader experience to provide input into
the study design to ensure research supports the needs
of this patient population and the community at large.
Community representatives will remain active in their
involvement of this study through regular updates with
members of the study team and will be encouraged to
offer suggestions on how to develop materials for plain
language summaries and dissemination. Further, the
clinicians on the study (CIT and RC) have high PCa
patient caseloads that allow them to discuss the design of
trials to target interventions to the needs of their patients.
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Limitations
Several limitations of the study warrant discussion. The
study is investigating Cr supplementation in individuals
with PCa undergoing ADT, thus generalisability to other
cancer populations is limited.18 Though a follow-up
period to analyse the sustainability of outcomes would
certainly be advantageous, limitations in funding and
resources make it difficult to undertake in this study. As
such the longer term benefits will not be elucidated.
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